Cancer- and chemotherapy-induced anemia: Clinical practice guidelines in oncology

George M. Rodgers, Pamela Sue Becker, Morey Blinder, David Cella, Asher Chanan-Khan, Charles Cleeland, Peter F. Coccia, Benjamin Djulbegovic, Jeffrey A. Gilreath, Eric H. Kraut, Ursula A. Matulonis, Michael M. Millenson, Denise Reinke, Joseph Rosenthal, Rowena N. Schwartz, Gerald Soff, Richard S. Stein, Gordana Vlahovic, Alva B. Weir

Research output: Contribution to journalReview articlepeer-review

118 Scopus citations

Abstract

Anemia is prevalent in 30% to 90% of patients with cancer. Anemia can be corrected through either treating the underlying cause or providing supportive care through transfusion with packed red blood cells or administration of erythropoiesis-stimulating agents (ESAs), with or without iron supplementation. Recent studies showing detrimental health effects of ESAs sparked a series of FDA label revisions and a sea change in the perception of these once commonly used agents. In light of this, the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Cancer- and Chemotherapy-Induced Anemia underwent substantial revisions this year. The purpose of these NCCN Guidelines is twofold: 1) to operationalize the evaluation and treatment of anemia in adult cancer patients, with an emphasis on those who are receiving concomitant chemotherapy, and 2) to enable patients and clinicians to individualize anemia treatment options based on patient condition.

Original languageEnglish (US)
Pages (from-to)628-653
Number of pages26
JournalJNCCN Journal of the National Comprehensive Cancer Network
Volume10
Issue number5
DOIs
StatePublished - May 1 2012

ASJC Scopus subject areas

  • Oncology

Fingerprint

Dive into the research topics of 'Cancer- and chemotherapy-induced anemia: Clinical practice guidelines in oncology'. Together they form a unique fingerprint.

Cite this